GJB2 and Hodgkins lymphoma: Across cohorts, GJB2 mutation carriers consistently exhibited equal or superior performance compared with other HL etiologies, and further studies have shown that even when controlling for residual hearing, age at implantation, and duration of implant use, DFNB1 children who use CIs exhibit greater gains in expressive language than non-DFNB1 children [103].